Clinical Outcomes of Carbon Ion Radiation Therapy for Malignant Peripheral Nerve Sheath Tumors

被引:0
|
作者
Fiore, Maria Rosaria [1 ]
Chalaszczyk, Agnieszka [1 ]
Barcellini, Amelia [1 ,2 ]
Vitolo, Viviana [1 ]
Fontana, Giulia [1 ]
Russo, Stefania [3 ]
Rotondi, Marco [1 ]
Molinelli, Silvia [3 ]
Mirandola, Alfredo [3 ]
Bazani, Alessia [3 ]
Orlandi, Ester [1 ,4 ]
机构
[1] CNAO Natl Ctr Oncol Hadrontherapy, Clin Dept, Radiat Oncol Unit, Pavia, Italy
[2] Univ Pavia, Dept Internal Med & Med Therapy, Pavia, Italy
[3] CNAO Natl Ctr Oncol Hadrontherapy, Phys Dept, Radiat Oncol Unit, Pavia, Italy
[4] Univ Pavia, Dept Clin Surg Diagnost & Pediat Sci, Pavia, Italy
关键词
RADIOTHERAPY; MANAGEMENT; SURVIVAL; EXPERIENCE; SARCOMA; MPNST;
D O I
10.1016/j.adro.2024.101619
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To investigate the outcome and toxicity of patients affected by malignant peripheral nerve sheath tumors (MPNSTs) treated with high-dose carbon ion radiation therapy (CIRT). Methods and Materials: We retrospectively analyzed the outcome of 23 patients with MPNSTs treated between July 2013 and December 2020. Out of these, 13 patients (56.5%) had incompletely resected tumors, 8 patients (34.7%) experienced recurrence after surgery, and 2 patients (8.7%) had unresectable tumors. Before CIRT treatment, 4 patients underwent a second surgery after the first local recurrence (LR), and 1 patient underwent a third surgery for the second local relapse of the disease. Six (26%) patients received neoadjuvant chemotherapy. The most frequent tumor site was the brachial plexus (n = 9; 39.1%). In 5 patients (21.7%), neurofibromatosis type 1 disorder was found, while 4 patients (17, 4%) had radiation-induced MPNSTs. The median CIRT prescribed total dose was 69.8 Gy (relative biological effectiveness; range, 54-76.8) delivered in a median of 16 fractions (range, 15-22). Eleven patients (47.82%) were treated according to a sequential boost protocol with a median prescribed dose to clinical target volume LR of Results: After a median follow-up time of 23 months (range, 3-100 months), the overall survival rates at 1 and 2 years were 82.38% and 61.51%, respectively. The 1-year and 2-year local relapse-free survival rates were 65.07% and 48.80%, respectively, and the 1-year and 2-year progression-free survival rates were 56.37% and 40.99%, respectively. No patients showed acute or late grade 4 toxicity or any treatment-related deaths. Ten patients (43.48%) reported acute toxicities of grade >= 2, which included dermatitis in 6 patients, mucositis in 2 patients, and peripheral neuropathy in 4 patients. Eight patients (34.78%) reported late toxicities of grade >= 2, mainly Conclusions: High-dose CIRT shows favorable local effects with acceptable toxicities in patients with gross residual and LR after surgery or unresectable malignant peripheral nerve sheath tumors. Advanced treatment modalities such as particle therapy should be (c) 2024 The Authors. Published by Elsevier Inc. on behalf of American Society for Radiation Oncology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页数:9
相关论文
共 50 条
  • [31] Radiation therapy in management of sporadic and neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors
    Kahn, Jenna
    Gillespie, Andy
    Tsokos, Maria
    Ondos, John
    Dombi, Eva
    Camphausen, Kevin
    Widemann, Brigitte C.
    Kaushal, Aradhana
    FRONTIERS IN ONCOLOGY, 2014, 4
  • [32] MALIGNANT PERIPHERAL-NERVE SHEATH TUMORS OF THE SKIN
    GEORGE, E
    SWANSON, PE
    WICK, MR
    JOURNAL OF CUTANEOUS PATHOLOGY, 1987, 14 (06) : 356 - 356
  • [33] Malignant peripheral nerve sheath tumors in neurofibromatosis 1
    King, AA
    DeBaun, RR
    Riccardi, VM
    Gutmann, DH
    AMERICAN JOURNAL OF MEDICAL GENETICS, 2000, 93 (05): : 388 - 392
  • [34] MAXILLOFACIAL MALIGNANT PERIPHERAL-NERVE SHEATH TUMORS
    COLMENERO, C
    RIVERS, T
    PATRON, M
    SIERRA, I
    GAMALLO, C
    JOURNAL OF CRANIO-MAXILLOFACIAL SURGERY, 1991, 19 (01) : 40 - 46
  • [35] Genetics of human malignant peripheral nerve sheath tumors
    Pemov, Alexander
    Li, Hua
    Presley, William
    Wallace, Margaret R.
    Miller, David T.
    NEURO-ONCOLOGY ADVANCES, 2020, 2 : i50 - i61
  • [36] Systemic Options for Malignant Peripheral Nerve Sheath Tumors
    Hassan, Ayesha
    Pestana, Roberto Carmagnani
    Parkes, Amanda
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2021, 22 (04)
  • [37] Ral Overactivation in Malignant Peripheral Nerve Sheath Tumors
    Bodempudi, Vidya
    Yamoutpoor, Farnaz
    Pan, Weihong
    Dudek, Arkadiusz Z.
    Esfandyari, Tuba
    Piedra, Mark
    Babovick-Vuksanovic, Dusica
    Woo, Richard A.
    Mautner, Victor F.
    Kluwe, Lan
    Clapp, D. Wade
    DeVries, George H.
    Thomas, Stacey L.
    Kurtz, Andreas
    Parada, Luis F.
    Farassati, Faris
    MOLECULAR AND CELLULAR BIOLOGY, 2009, 29 (14) : 3964 - 3974
  • [38] A-Z of malignant peripheral nerve sheath tumors
    Kamran, S. C.
    Shinagare, A. B.
    Howard, S. A.
    Hornick, J. L.
    Ramaiya, N. H.
    CANCER IMAGING, 2012, 12 (03): : 475 - 483
  • [39] Systemic Options for Malignant Peripheral Nerve Sheath Tumors
    Ayesha Hassan
    Roberto Carmagnani Pestana
    Amanda Parkes
    Current Treatment Options in Oncology, 2021, 22
  • [40] MALIGNANT PERIPHERAL NERVE SHEATH TUMORS OF ORAL CAVITY
    HAMMOND, HL
    CALDERWOOD, RG
    ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY AND ENDODONTOLOGY, 1969, 28 (01): : 97 - +